The outlook assumes net sales for Linzess will be between $1.125 billion and $1.175 billion in FY2026. ・U.S. FDA had approved Ironwood’s Linzess capsules for pediatric patients, in November. ・Linzess ...

We recently published 10 Small Stocks with Mighty Gains. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) is one of the top-performing stocks on Wednesday. Ironwood Pharmaceuticals soared by 23.32 percent ...

Ironwood Pharmaceuticals (IRWD) stock rebounds after Linzess price cut news proves less damaging than feared, with Medicare-only impact and list price rarely paid. IRWD's diversification via Vectiv ...

Detailed price information for Ironwood Pharmaceuti (IRWD-Q) from The Globe and Mail including charting and trades.

1 Ironwood’s U.S. collaborative arrangements revenue includes reimbursement from AbbVie for a portion of Ironwood’s commercial expenses related to sales of LINZESS in the U.S. The FY2025 total revenue ...